FDA Expands Approval of Gilenya to Treat MS in Paediatric Patients
The US Food and Drug Administration (FDA) has approved Gilenya (fingolimod) to treat relapsing multiple sclerosis (MS) in children and adolescents aged 10 years and older. This is the first FDA approval of a drug to treat MS in paediatric patients. ‘For the first time, we have an FDA-approved treatment specifically for children and adolescents [...]